| scholarly article | Q13442814 |
| P50 | author | Martie van Tongeren | Q28468962 |
| John K. Field | Q42754256 | ||
| P2093 | author name string | T Liloglou | |
| A Cassidy | |||
| S W Duffy | |||
| R D Page | |||
| J P Myles | |||
| P2860 | cites work | The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? | Q24804857 |
| Global cancer statistics, 2002 | Q27860562 | ||
| Survival of patients with stage I lung cancer detected on CT screening | Q28270460 | ||
| Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force | Q31057585 | ||
| Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers | Q33706159 | ||
| When can a risk factor be used as a worthwhile screening test? | Q33791003 | ||
| Variations in lung cancer risk among smokers. | Q34184504 | ||
| Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives | Q36611864 | ||
| Lung cancer risk prediction: a tool for early detection | Q36631869 | ||
| Lung carcinoma in African Americans | Q36720878 | ||
| Lung cancer screening by spiral CT. What is the optimal target population for screening trials? | Q40620320 | ||
| Occupational exposure to crystalline silica and risk of lung cancer: a multicenter case-control study in Europe | Q43642664 | ||
| Cancer risk prediction models: a workshop on development, evaluation, and application | Q44065523 | ||
| Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. | Q47373574 | ||
| Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. | Q51933968 | ||
| Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. | Q53367685 | ||
| The Liverpool Lung Project research protocol | Q58375977 | ||
| Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
| Lung cancer after radiation therapy for breast cancer | Q70708988 | ||
| Previous cancer and radiotherapy as risk factors for lung cancer in lifetime nonsmokers | Q72553215 | ||
| Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA | Q73435242 | ||
| Lung cancer risks in women with previous breast cancer | Q74444419 | ||
| A risk model for prediction of lung cancer | Q80242314 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 270-276 | |
| P577 | publication date | 2007-12-18 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | The LLP risk model: an individual risk prediction model for lung cancer | |
| P478 | volume | 98 |
| Q39738163 | A Novel Pathway-Based Approach Improves Lung Cancer Risk Prediction Using Germline Genetic Variations |
| Q36116188 | A Perturbation Method for Inference on Regularized Regression Estimates |
| Q37114501 | A clinical risk prediction model for Barrett esophagus. |
| Q44325877 | A concordance index for matched case-control studies with applications in cancer risk |
| Q34265269 | A review of cancer risk prediction models with genetic variants |
| Q34966064 | A risk model for lung cancer incidence |
| Q35688591 | A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor |
| Q28384749 | A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases |
| Q33750741 | AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer |
| Q37237879 | An Automated Method for Identifying Individuals with a Lung Nodule Can Be Feasibly Implemented Across Health Systems |
| Q33788568 | An expanded risk prediction model for lung cancer |
| Q36185930 | An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice |
| Q35065320 | An ongoing case-control study to evaluate the NHS breast screening programme |
| Q88034408 | Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions |
| Q33936367 | Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention |
| Q87128867 | Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men |
| Q35884911 | Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial |
| Q47677172 | Best of lung cancer session presented during ERS 2017 Chinese language day: lung cancer screening. |
| Q62492568 | Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges |
| Q26747784 | Biomarkers of risk to develop lung cancer in the new screening era |
| Q34840130 | Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era |
| Q39612965 | Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer |
| Q47635251 | CT lung cancer screening in the UK. |
| Q38166082 | CT screening for lung cancer: countdown to implementation |
| Q33560334 | Cancer stem cell marker Musashi-1 rs2522137 genotype is associated with an increased risk of lung cancer |
| Q37111529 | Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q36247926 | China national lung cancer screening guideline with low-dose computed tomography (2015 version) |
| Q35061539 | Clinical characteristics and prognosis of incidentally detected lung cancers |
| Q36882598 | Combining Telomerase Reverse Transcriptase Genetic Variant rs2736100 with Epidemiologic Factors in the Prediction of Lung Cancer Susceptibility |
| Q33825806 | Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling |
| Q41635556 | Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial |
| Q34059668 | Comparison of discriminatory power and accuracy of three lung cancer risk models |
| Q27021984 | Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement |
| Q28285393 | Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial |
| Q89738416 | DNA Repair Biomarker for Lung Cancer Risk and its Correlation With Airway Cells Gene Expression |
| Q36199283 | Decision tree of occupational lung cancer using classification and regression analysis |
| Q30386349 | Demonstration program of population-based lung cancer screening in China: Rationale and study design |
| Q64080751 | Developing prediction models for clinical use using logistic regression: an overview |
| Q33788556 | Development and validation of a lung cancer risk prediction model for African-Americans |
| Q49968289 | Development of a risk prediction model for lung cancer: The Japan Public Health Center-based Prospective Study |
| Q64236801 | Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study |
| Q92982834 | EU Policy on Lung Cancer CT Screening 2017 |
| Q91235996 | Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model |
| Q30530822 | Eliciting symptoms interpreted as normal by patients with early-stage lung cancer: could GP elicitation of normalised symptoms reduce delay in diagnosis? Cross-sectional interview study |
| Q86906665 | Epidemiology of Lung Cancer |
| Q27023830 | Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q60643311 | Estimating the risk of PTSD in recent trauma survivors: results of the International Consortium to Predict PTSD (ICPP) |
| Q47689794 | European position statement on lung cancer screening |
| Q57559017 | European randomized lung cancer screening trials: Post NLST |
| Q89099836 | Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement |
| Q36300970 | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
| Q90316688 | Evaluation of cardiovascular risk in a lung cancer screening cohort |
| Q34611247 | Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts |
| Q92310082 | Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models |
| Q34976530 | Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer |
| Q44171693 | Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group |
| Q30535897 | From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de [...] |
| Q27027720 | Genetic risk prediction in complex disease |
| Q35511905 | Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm |
| Q39344447 | Implementation of lung cancer CT screening in the Nordic countries |
| Q26784107 | Implementing lung cancer screening in the real world: opportunity, challenges and solutions |
| Q88813557 | Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening |
| Q36992197 | Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model |
| Q39181335 | Increased lung cancer risk among patients with pneumococcal pneumonia: a nationwide population-based cohort study |
| Q34585888 | Individualized risk prediction model for lung cancer in Korean men |
| Q36258075 | Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions |
| Q100526157 | Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives |
| Q33603681 | Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors |
| Q35090585 | Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. |
| Q28384727 | Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository |
| Q38238438 | Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers |
| Q57641629 | Lung cancer screening with low-dose computed tomography |
| Q47819582 | Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. |
| Q35567559 | Lung cancer screening: identifying the high risk cohort |
| Q26829339 | Lung cancer screening: past, present and future |
| Q38155065 | Lung cancer screening: review and performance comparison under different risk scenarios |
| Q34195009 | Lung cancer screening: subsequent evidences of national lung screening trial |
| Q36858245 | Lung cancer screening: the way forward |
| Q51555862 | Lung cancer screening: what we can learn from UKLS? |
| Q24630167 | Lung cancer: epidemiology, etiology, and prevention |
| Q24625044 | Lung carcinogenesis by tobacco smoke |
| Q37083077 | Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas |
| Q35663480 | Mouse double minute-2 homolog (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese population |
| Q58068364 | MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model |
| Q37514797 | Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate |
| Q35859020 | Occupational risk factors have to be considered in the definition of high-risk lung cancer populations |
| Q37643215 | Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers |
| Q37386375 | Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan |
| Q47105201 | Pleural plaques in lung cancer screening by low-dose computed tomography: prevalence, association with lung cancer and mortality |
| Q30610197 | Predicting lung cancer prior to surgical resection in patients with lung nodules |
| Q85474754 | Predicting the risk of an asthma attack: the way ahead? |
| Q57178729 | Prediction of acute myeloid leukaemia risk in healthy individuals |
| Q34507724 | Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model |
| Q33599090 | Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy |
| Q64928296 | Prediction of the 1-Year Risk of Incident Lung Cancer: Prospective Study Using Electronic Health Records from the State of Maine. |
| Q37045787 | Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study |
| Q64051799 | Presentation of lung cancer in primary care |
| Q93147172 | Prevalence and analysis of tobacco use disorder in patients diagnosed with lung cancer |
| Q90272427 | Prevalence, Symptom Burden and Under-Diagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort |
| Q28392363 | Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium |
| Q28387390 | Previous lung diseases and lung cancer risk: a systematic review and meta-analysis |
| Q38131167 | Prospects for population screening and diagnosis of lung cancer |
| Q35560984 | Quantitative CT assessment of emphysema and airways in relation to lung cancer risk |
| Q60925939 | Recognising Lung Cancer in Primary Care |
| Q30498812 | Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic |
| Q54064855 | Reply: Lung Cancer Screening: The Balance between Harm and Benefit. |
| Q35902754 | Risk Classification with an Adaptive Naive Bayes Kernel Machine Model |
| Q40040989 | Risk assessment models for genetic risk predictors of lung cancer using two-stage replication for Asian and European populations |
| Q92477500 | Risk prediction models for lung cancer: Perspectives and dissemination |
| Q36334146 | Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study |
| Q38340341 | Screening and early detection efforts in lung cancer |
| Q64100057 | Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors |
| Q26799888 | Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals |
| Q37246295 | Screening for lung cancer with low-dose computed tomography: a review of current status |
| Q30543321 | Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. |
| Q50448070 | Searching for red shirts. Emphysema as a lung cancer screening criterion? |
| Q47097284 | Selecting high-risk individuals for lung cancer screening; the use of risk prediction models vs. simplified eligibility criteria |
| Q37594556 | Selection criteria for lung-cancer screening |
| Q37691888 | Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening |
| Q36335248 | Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma |
| Q45178701 | Symptom lead time distribution in lung cancer: natural history and prospects for early diagnosis |
| Q37198867 | Targeting of low-dose CT screening according to the risk of lung-cancer death |
| Q35995304 | The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients |
| Q38133416 | The contribution of risk prediction models to early detection of lung cancer |
| Q35805572 | The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model |
| Q36453693 | The effect of metformin and thiazolidinedione use on lung cancer in diabetics |
| Q30317739 | The role of DNA methylation as biomarkers in the clinical management of lung cancer |
| Q37148034 | Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women |
| Q37173553 | Trends in Subpopulations at High Risk for Lung Cancer |
| Q36577246 | UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening |
| Q34714126 | UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer |
| Q57306270 | Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing |
| Q35678408 | Unique volatolomic signatures of TP53 and KRAS in lung cells |
| Q92841495 | Update on screening for lung cancer |
| Q28388931 | Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention |
| Q37614587 | Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer |
| Q50131710 | Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials |
| Q35048580 | What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? |
| Q35985104 | What proportion of lung cancer in never-smokers can be attributed to known risk factors? |
| Q52978329 | [Lung cancer screening - risk stratification : Who should undergo screening?]. |
| Q90444745 | [Lung cancer screening] |
| Q55426257 | [Present Situation of Lung Cancer Screening Methods]. |
| Q53069561 | [The importance of risk models for management of pulmonary nodules]. |
Search more.